A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

An Open-label, Phase 1 Study to Characterize the Effects of a Strong CYP3A4 Inducer on the Pharmacokinetics of MK-8527 in Healthy Adult Participants

The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time when MK-8527 is given alone and with the medication CBZ.

Inclusion Criteria:

Inclusion criteria include, but are not limited to:

• Is a healthy, adult, male or female of non-childbearing potential only, 18-55 years of age, inclusive
• Is a continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior

Exclusion Criteria:

Exclusion criteria include, but are not limited to:

• Has a history or presence of:

  • Seizures (except for febrile seizure), or is at an increased risk for seizures
  • Family history of severe dermatologic reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome
  • Clinically meaningful hematologic diseases, bone marrow disorders, or hematologic adverse reactions to other medications
  • Depression, unusual changes in mood or behavior or suicidal thoughts or behavior
  • Hypersensitivity reaction to anticonvulsant therapy (including phenytoin, primidone, and phenobarbital)
  • Clinically significant eye disease
  • Cardiac conduction disturbance, including second-and third-degree atrioventricular heart block

• Shown to carry or be positive for HLA-A*11:01, HLA-A*31:01, HLA-B*15:02, HLA-B*15:08, HLA-B*15:11, HLA-B*15:21, HLA-B*15:30, or HLA-B*15:31 alleles.